Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new product boosts. Contract services and APIs are set for moderate gains. Sun Pharma and Lupin are poised for leadership. Cipla and Dr Reddy’s face softer US sales. Divi’s Laboratories expects strong custom synthesis growth.
Trump’s trade chief says ‘deal’s a deal’ for economies with capped US tariffs
America’s trade representative assures that new tariffs will respect existing agreements. He stated that a deal is a deal for nations like the European Union
June 4, 2026